tetano
Editor, Senior Moderator
Clin Epidemiol Glob Health
. May-Jun 2022;15:101013.
doi: 10.1016/j.cegh.2022.101013. Epub 2022 Mar 19.
Mucormycosis: A new threat to Coronavirus disease 2019 with special emphasis on India
Deganta Ghosh[SUP] 1 [/SUP], Sagardeep Dey[SUP] 1 [/SUP], Himanko Chakraborty[SUP] 1 [/SUP], Sneha Mukherjee[SUP] 1 [/SUP], Ankita Halder[SUP] 1 [/SUP], Akash Sarkar[SUP] 1 [/SUP], Pallab Chakraborty[SUP] 2 [/SUP], Rajdeep Ghosh[SUP] 3 [/SUP], Joy Sarkar[SUP] 1 [/SUP]
Affiliations
Abstract
The main reason for the growth of mucormycosis in people with Coronavirus disease-2019 (COVID-19) is mainly produced by Rhizopus spp. The infective mechanisms and issues recognized in Rhizopus spp. are the cell wall, germination proteins, and enzymes assisted to iron sequestration, CotH protein, and positive regulation of the GRP78 cell receptor. Mucormycosis is mainly caused by the Rhizopus spp. such as R. oryzae, R. microsporus, R. arrhizus, R. homothallicus, etc. that are gifted to numerous host defense mechanisms and attribute to the endothelium via specific receptors, GRP78 simplifying their endocytosis and angio-invasion. Factors such as hyperglycemia, elevated iron concentrations, and ketoacidosis have been shown to contribute to the pathogenesis in the tentative situation. The analytical data of 'black fungus disease' or 'mucormycosis', specify India reported for about 42.3% of published cases, followed by the USA about 16.9%, Iraq, Bangladesh, Iran, Paraguay, and 1 case each from Brazil, Mexico, Italy, UK, China, France, Uruguay, Turkey, and Austria. The COVID-19 infection is maybe a predisposing factor for mucormycosis and is related to a high mortality rate. Early recognition and restriction of hyperglycemia, liposomal amphotericin B, and surgical debridement are the bases in the successful managing of mucormycosis.
Keywords: COVID-19; Corticosteroid; Diabetics; Mucormycosis; Rhizopus.
. May-Jun 2022;15:101013.
doi: 10.1016/j.cegh.2022.101013. Epub 2022 Mar 19.
Mucormycosis: A new threat to Coronavirus disease 2019 with special emphasis on India
Deganta Ghosh[SUP] 1 [/SUP], Sagardeep Dey[SUP] 1 [/SUP], Himanko Chakraborty[SUP] 1 [/SUP], Sneha Mukherjee[SUP] 1 [/SUP], Ankita Halder[SUP] 1 [/SUP], Akash Sarkar[SUP] 1 [/SUP], Pallab Chakraborty[SUP] 2 [/SUP], Rajdeep Ghosh[SUP] 3 [/SUP], Joy Sarkar[SUP] 1 [/SUP]
Affiliations
- PMID: 35342843
- PMCID: PMC8934183
- DOI: 10.1016/j.cegh.2022.101013
Abstract
The main reason for the growth of mucormycosis in people with Coronavirus disease-2019 (COVID-19) is mainly produced by Rhizopus spp. The infective mechanisms and issues recognized in Rhizopus spp. are the cell wall, germination proteins, and enzymes assisted to iron sequestration, CotH protein, and positive regulation of the GRP78 cell receptor. Mucormycosis is mainly caused by the Rhizopus spp. such as R. oryzae, R. microsporus, R. arrhizus, R. homothallicus, etc. that are gifted to numerous host defense mechanisms and attribute to the endothelium via specific receptors, GRP78 simplifying their endocytosis and angio-invasion. Factors such as hyperglycemia, elevated iron concentrations, and ketoacidosis have been shown to contribute to the pathogenesis in the tentative situation. The analytical data of 'black fungus disease' or 'mucormycosis', specify India reported for about 42.3% of published cases, followed by the USA about 16.9%, Iraq, Bangladesh, Iran, Paraguay, and 1 case each from Brazil, Mexico, Italy, UK, China, France, Uruguay, Turkey, and Austria. The COVID-19 infection is maybe a predisposing factor for mucormycosis and is related to a high mortality rate. Early recognition and restriction of hyperglycemia, liposomal amphotericin B, and surgical debridement are the bases in the successful managing of mucormycosis.
Keywords: COVID-19; Corticosteroid; Diabetics; Mucormycosis; Rhizopus.